Skip to main content
. 2023 Mar 2;78(12):2426–2434. doi: 10.1093/gerona/glad075

Table 2.

Number of Events and Incidence of Hypoglycemia in 1:1 PS Matched Cohorts of SGLT2i and DPP-4i (GLP-1RA) Initiators

Comparison Outcomes Number of Matched Pairs SGLT2i Initiators Comparator Initiators Rate Differences Per 1 000 PY (95% CI) Hazard Ratios (95% CI)
No. of events (rate/1 000 PY) No. of events (rate/1 000 PY)
SGLT2i vs DPP-4i Hypoglycemia (inpatient + ED) 82,994 692 (9.8) 987 (13.0) −3.21 (−4.29, −2.12) 0.75 (0.68, 0.83)
Hypoglycemia (inpatient) 82,994 77 (1.1) 96 (1.0) −0.17 (−0.52, 0.18) 0.87 (0.65, 1.18)
Hypoglycemia (ED) 82,994 689 (9.7) 986 (13.0) −3.24 (−4.33, −2.15) 0.75 (0.68, 0.83)
SGLT2i vs GLP-1RA Hypoglycemia (inpatient + ED) 88,726 848 (11.1) 898 (12.5) −1.33 (−2.44, −0.23) 0.90 (0.82, 0.98)
Hypoglycemia (inpatient) 88,726 92 (1.2) 75 (1.0) 0.17 (−0.17, 0.51) 1.16 (0.85, 1.57)
Hypoglycemia (ED) 88,726 842 (11.1) 896 (12.4) −1.38 (−2.49, −0.28) 0.89 (0.81, 0.98)

Note: DPP4i = dipeptidyl peptidase-4 inhibitors; ER = emergency room; GLP-1RA = glucagon-like peptide-1 receptor agonist; PS = propensity-score; PY = person-years; SGLT2i = sodium-glucose cotransporter 2 inhibitors.